Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth hormone-releasing hormone, amidated at the C-terminus. This fragment retains the full biological activity of the 44-amino-acid native hormone, which is why GHRH(1-29)-NH₂ became the standard research and clinical form. The published literature typically identifies the compound by that sequence designation rather than by the name sermorelin, a point worth knowing when searching the record.
Mechanistic context
Sermorelin acts at the GHRH receptor on anterior pituitary somatotrophs, stimulating synthesis and release of growth hormone. Because it operates upstream of the pituitary rather than replacing growth hormone directly, secretion remains subject to normal feedback regulation, including somatostatin inhibition. This preserved feedback is the principal mechanistic distinction between GHRH analogues and exogenous growth hormone, and it is the reason the two produce different secretory patterns.
Published findings
Barron and colleagues (1985) reported growth hormone responses to GHRH(1-29)-NH2 and a D-Ala2 analogue in normal men, establishing activity of the truncated fragment in humans and comparing it against a modified analogue.
Ross and colleagues (1990) reported that subcutaneous GHRH augmented pulsatile nocturnal growth hormone release in growth hormone-insufficient children, while also noting that it may raise basal secretion — a finding that distinguishes pulse amplification from baseline elevation, which are physiologically different outcomes.
Neyzi and colleagues (1993) compared growth responses to GHRH(1-29)-NH2 against growth hormone itself, and Chen and colleagues (1993) reported a comparative study of the two for stimulation of growth in children with growth hormone deficiency. Both are direct comparator studies, which makes them more informative than single-arm reports.
Scope and limitations of the evidence
The sermorelin literature includes genuine human clinical work, and the comparator designs against growth hormone are a methodological strength. However, the studies cited are conducted in specific populations — growth hormone-deficient children and normal adult men — and results should not be generalised beyond them.
The literature is also dated, concentrated in the mid-1980s to early 1990s. Assay methodology for growth hormone and IGF-1 has changed substantially since, and absolute values reported in that era are not directly comparable with contemporary measurements.
Use in experimental design
Because the compound acts upstream and preserves feedback, endpoints should distinguish pulse amplitude, pulse frequency and basal concentration — the Ross findings show these can move independently. Frequent sampling is required to resolve them. Nocturnal timing is relevant, since endogenous growth hormone secretion is concentrated in slow-wave sleep and the Ross work specifically examined nocturnal release.
Analytical and handling notes
Each lot is supplied with a certificate of analysis reporting RP-HPLC purity, mass identification by ESI-MS and label claim recovery, together with an independent ICP-MS elemental impurities report. Purity figures apply to the specific lot tested and should be read against the lot documentation rather than inferred from generic reference material. Storage guidance appears on the technical data sheet; the exact supplied salt form, counterion and hydration state are lot and supplier specific and should be reconciled against supplier documentation before quantitative work.
This material is supplied for laboratory research use only. It is not a drug, is not intended for human or veterinary use, and no statement above should be read as a claim of therapeutic effect.
